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Vascular dementia: a 
consequence of hypertension
Stroke, renal failure, heart failure, and ath-
erosclerosis are commonly recognized as 
consequences of hypertension; however, 
the association between hypertension and 
cognitive decline is not as widely appreci-
ated. In the 1990s, Launer and colleagues 
reported that for every 10 mmHg increase 
in midlife systolic pressure, there is a 5% 
increase in the incidence of cognitive 
decline, even after correction for stroke, 
coronary artery disease, and subclinical 
atherosclerosis (1). More recently, Ninoya-
ma et al. reported that subjects with mid-
life hypertension had a five-fold increase 
in the risk of developing vascular dementia 
as compared with those without hyperten-
sion (2). To be fair, the association between 
hypertension and impaired cognition has 
not been uniformly reported, and other 
groups have reported a J-shaped curve, 
which in fact correlates better cognition 
with higher levels of blood pressure in very 
old individuals (3). A major problem with 
these studies is the lack of a precise defi-
nition of vascular dementia and difficulty 
in distinguishing this condition from Alz-
heimer’s disease. Vascular dementia is tra-
ditionally associated with stroke, sudden 
declines in cognition, or obvious perturba-
tions of cerebral perfusion; however, these 
clinical clues are imprecise and often not 
apparent. Hypertension affects the small 
brain arterioles, leading to diffuse cerebral 
impairment, without localizing signs and 
with insidious progression, thereby mak-
ing a clear distinction from Alzheimer’s 
disease difficult. To complicate matters, in 
more than half of all cases of dementia, the 
pathology is mixed, with vascular disease 
coexisting with amyloid deposits (reviewed 
in ref. 4). Recently, accumulation of amy-
loid-β has been observed in brains of 
hypertensive animals (5), and these amy-
loid deposits are reduced in mice lacking 
the angiotensin II type 1 receptor (6). Fas-
cinatingly, β-amyloid has recently been 
shown to activate α-1 adrenergic receptors 
by binding the first extracellular loop and 
thereby causing vasoconstriction (7). Thus, 
there is substantial interplay between the 
pathology of Alzheimer’s disease and vas-
cular dementia.
A fundamental aspect of hypertension 
is the profound vascular alterations that 
occur. Hypertension causes remodeling, 
fibrosis, and alterations of vascular tone 
that promote vasoconstriction, largely due 
to impaired endothelial function. Changes 
in vascular tone are often mediated by over-
production of ROS within the vessel, which 
directly promotes vasoconstriction and 
leads to oxidative inactivation of endotheli-
um-derived nitric oxide. More than twenty 
years ago, it was recognized that angioten-
sin II (Ang II) is a potent stimulus for ROS 
production in vascular cells via activation 
of the NADPH oxidase (8). It is now recog-
nized that Ang II can activate the NADPH 
oxidase in many cells and that this under-
lies many of the biological actions of Ang II, 
including vasoconstriction, sodium reten-
tion by the kidney, and sympathetic outflow 
from the brain (9). Indeed, scavenging of 
superoxide, or deletion of components of 
the NADPH oxidase, markedly blunts the 
hypertensive response to Ang II. Block-
ade of the angiotensin system also inhib-
its NADPH oxidase activity and improves 
endothelium-dependent vasodilatation in 
patients with hypertension. In the brain, 
endothelial signaling is critical for the func-
tion of the neurovascular unit (NVU), which 
allows coupling of nutrient delivery to neu-
rons. As in other vessels, increased ROS 
formation plays a major role in disrupting 
NVU function and coupling (10).
There has been substantial inter-
est in the cell type within the vessel wall 
responsible for ROS production, with 
a debate centered on whether intrinsic 
vascular cells, such as endothelial and 
vascular smooth muscle cells, or infil-
trating inflammatory cells are the main 
ROS producers (11). In recent years, it has 
become increasingly evident that innate 
and adaptive immunity contributes to 
hypertension and the attendant end-or-
gan damage. In peripheral vessels, mono-
cytes, macrophages, and T cells invade 
the perivascular fat and adventitia and 
release mediators that promote vascular 
remodeling, fibrosis, and dysfunction 
(12–14). The adventitia is also home to 
resident macrophages with an M2 repar-
ative phenotype. Professional phagocytes 
like these are sources of NADPH oxidase–
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Cognitive impairment, an underappreciated consequence of hypertension, 
is linked to cerebral arteriolar disease through poorly defined mechanisms. 
A study by Faraco et al. in this issue of the JCI points to perturbations of 
neurovascular unit coupling caused by perivascular macrophages (PVMs) 
as a cause of hypertension-related cognitive impairment. Angiotensin II 
(Ang II) was shown to activate PVMs, causing them to produce superoxide 
and thereby alter the proper functioning of the adjacent arterioles. Faraco 
and colleagues also show that disruption of the blood-brain barrier occurs 
in hypertension, allowing circulating Ang II to access PVMs. This study 
provides important new insight into the role of inflammatory cells in the 
genesis of vascular dementia.
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effects were confined to the local function 
of cerebral arterioles and their NVUs and 
were therefore not systemic. These inter-
actions of PVMs with the NVU are illus-
trated in Figure 1.
Future questions
Faraco et al. carefully defined PVMs by 
surface marker expression and showed 
that this cell population is different from 
microglial cells. While Faraco and col-
leagues referred to PVMs as resident cells, 
their bone marrow transplantation stud-
ies clearly show that PVMs are derived 
from the bone marrow. Future studies to 
examine how PVMs are signaled to traffic 
from the marrow and how these cells find 
access to the cerebral arteriolar perivascu-
lar space will be very informative. PVMs 
express high levels of CD206, similar to 
M2 macrophages; however, determining 
the precise phenotype of these cells will 
require further analysis. Obviously, PVMs 
are capable of generating ROS but proba-
bly produce other mediators, such as cyto-
kines and metalloproteinases that affect 
the vessel. PVMs also likely to respond to 
signals other than Ang II. A comprehen-
sive transcriptomic analysis of cerebral 
cells like PVMs, similar to that being per-
formed by the Functional Annotation of 
the Mammalian Genome (FANTOM) con-
sortium, will provide further insight into 
the function and phenotype of PVMs (16).
Traditionally, the blood-brain barrier 
was thought to exclude hormones like Ang 
II from most of the brain, suggesting that 
any central signaling mediated by Ang II 
must be due to its actions on the circum-
ventricular organs, which have a poorly 
formed blood brain-barrier, or due to Ang 
II produced locally within the brain. An 
important contribution of the study by 
Faraco et al. is the demonstration that cir-
culating Ang II can cross the blood-brain 
barrier in hypertension and, thus, that Ang 
sion and BPH/2J mice that have life-long 
hypertension — revealed that PVMs are 
critical for impairing cerebral cortical arte-
riolar function in hypertension. Using ele-
gant bone marrow transplantation studies, 
Faraco and colleagues demonstrated that 
PVMs require the Ang II type 1 receptor 
and the NADPH oxidase subunit NOX2 
to alter arteriolar function. Importantly, 
in BPH/2J mice, PVM depletion improved 
behavior in the Barnes maze test and in a 
novel object recognition test, suggesting 
that the vascular dysfunction caused by 
PVMs can lead to cognitive impairment. 
Of note, the manipulations to alter PVM 
numbers and function did not affect sys-
temic blood pressure, showing that these 
derived ROS, and, therefore, even a few 
such cells could contribute to oxidative 
signaling and injury if activated.
Perivascular macrophages:  
the missing link
In this issue, Faraco et al. provide an excit-
ing link between hypertension and cog-
nitive decline (15). Specifically, they have 
shown that perivascular macrophages 
(PVMs) closely associate with cortical arte-
rioles and that hypertension causes disrup-
tion of the blood-brain barrier, allowing 
Ang II to reach these cells. Depletion of 
PVMs via intracerebroventricular injection 
of clodronate in two models of hyperten-
sion — a chronic fourteen-day Ang II infu-
Figure 1. Proposed role of PVMs in cognitive 
dysfunction. Hypertension leads to disruption 
of the blood-brain barrier, allowing Ang II and 
probably other neurohumoral agents to stimu-
late the production of ROS, including superoxide 
(O2
.–), by PVMs. Superoxide and other ROS pro-
mote vasoconstriction, endothelial dysfunction, 
and oxidative injury in cerebral arterioles. These 
events cause dysfunction of the NVU, leading to 
cognitive impairment. AT1R, AT1 receptor; BBB, 
blood-brain barrier.
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II not only affects cerebral perfusion, but 
likely signals other events, like increased 
sympathetic outflow from centers such as 
the paraventricular nucleus and the brain 
stem. Future studies using techniques such 
as those applied by Faraco et al. will be use-
ful in defining the access of Ang II and oth-
er systemic mediators to various brain cen-
ters. Additional investigation into how the 
blood-brain barrier is disrupted in hyper-
tension will also be of substantial interest.
Finally, the study by Faraco and col-
leagues (15) offers hints as to how we 
might use currently available therapies to 
reduce cognitive impairment. The results 
of this study suggest that AT1 receptor 
antagonists might be helpful in prevent-
ing cognitive impairment in hyperten-
sive patients. Indeed, losartan has proven 
effective in ameliorating brain pathology 
and protecting brain function in a mouse 
model of Alzheimer’s disease (17). Smaller 
clinical studies have suggested a benefit of 
AT1 receptor blockers in preventing cog-
nitive impairment, although the results of 
larger trials have been disappointing (18). 
The length of treatment and timing of 
therapy may be important considerations. 
Newer agents, such as NOX inhibitors or 
scavengers of oxidative products, might 
also be effective (19). The effect of drugs 
like these on the PVM is now an important 
focus of future research.
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